| Exclusion Criteria: | 1) The subject has received anticancer treatment (e.g., chemotherapy, radiotherapy, cytokines) within 14 days (6 weeks for nitrosoureas or mitomycin C) before the first dose of study drug, or has not recovered to Grade </= 1 from AEs due to agents administered more than 30 days earlier.
2) The subject has participated in a clinical trial and has received an investigational product within 21 days prior to the first dosing day in the current study.
3) The subject has known brain metastases.
4) The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
5) History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Study Physician, contraindicates their participation.
6) The subject is known to be positive for the human immunodeficiency virus (HIV).
7) Subjects who have had partial or complete gastrectomy.
8) Pregnant females as determined by positive B-hCG test at screening or prior to dosing.
9) Lactating females.
10) Unwillingness or inability to follow the procedures outlined in the protocol. |